The advance in study on novel non-anti-TNF-α drugs in the treatment of Crohn′s disease
10.3760/cma.j.cn101480-20200103-00001
- VernacularTitle:新型非抗肿瘤坏死因子-α单克隆抗体药物治疗克罗恩病的研究进展
- Author:
Chunhui OUYANG
1
;
Xiaoping WU
1
Author Information
1. 中南大学湘雅二医院消化内科，长沙 410000
- Publication Type:Journal Article
- Keywords:
Crohn′s disease;
Anti-interleukin;
Anti-integrin;
JAK inhibitor;
Antisense oligonucleotide drugs
- From:
Chinese Journal of Inflammatory Bowel Diseases
2020;04(2):100-103
- CountryChina
- Language:Chinese
-
Abstract:
Crohn′s disease (CD) that affects the gastrointestinal tract is a chronic, non-specific transmural inflammatory disease, and its pathogenesis is not clear at present. Traditional drug therapy includes glucocorticoids and immunosuppressive agents and so on. In nearly two decades, biological agents represented by anti-tumor necrosis factor (TNF) -α monoclonal antibodies have greatly changed the prognosis of CD. However, its clinical application still faces challenges, such as primary non-response or secondary non-response. With the in-depth study of the pathophysiology of CD, novel therapeutic targets drugs are emerging continuously. This article summarizes and discusses the research progress of these novel drugs to provide references for clinical treatment.
